A Phase I, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZD5069 in Healthy Japanese Subjects After Single and Multiple Ascending Doses.
Phase of Trial: Phase I
Latest Information Update: 27 Jun 2015
At a glance
- Drugs AZD 5069 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
- 17 Mar 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Dec 2010 Planned end date changed from 1 Jul 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.